

# CHARLES ARTHUR PELOQUIN, PHARM.D.

## CURRICULUM VITAE

### I. Personal History

Present Rank: Professor

Present Address: 4404 NW 51<sup>st</sup> Drive, Gainesville, FL 32606

Citizenship: USA

### II. Educational History

12/81 Bachelor of Science, Pharmacy (Magna cum Laude), University of Connecticut

5/86 Doctor of Pharmacy, Philadelphia College of Pharmacy and Science

### III. Professional History

5/80 – 9/80 Medicinal Chemist, University of Connecticut School of Pharmacy, Storrs  
5/81 – 9/81 Medicinal Chemist, University of Connecticut School of Pharmacy, Storrs  
12/81 – 7/82 Intern in Pharmacy, Saint Francis Hospital and Medical Center, Hartford, CT  
7/82 – 6/83 A.S.H.P. Resident in Hospital Pharmacy Duke University Medical Center, Durham, NC  
7/83 – 2/84 Clinical Pharmacist, General Surgery, Duke University Medical Center  
3/84 – 8/84 Clinical Pharmacist, General Medicine, Duke University Medical Center  
8/84 – 3/85 Staff Pharmacist Thomas Jefferson University Hospital, Philadelphia, PA  
7/86 – 8/88 A.C.C.P. Fellow, Infectious Diseases and Pharmacokinetics  
The Clinical Pharmacokinetics Laboratory, Millard Fillmore Hospital, Buffalo, NY  
7/88 – 3-09 Director, Infectious Disease Pharmacokinetics Laboratory  
National Jewish Health, 1400 Jackson Street, Denver, CO 80206

7/88 Assistant Faculty Member, Department of Medicine  
4/94 Associate Faculty Member, Department of Medicine  
7/01 Senior Faculty Member, Department of Medicine  
National Jewish Medical and Research Center

9/88 – 12/94 Adjoint Assistant Professor of Pharmacy  
1/95 – 11/01 Adjoint Associate Professor of Pharmacy  
11/01 – 9/05 Adjoint Professor of Pharmacy  
9/05 – 3/09 Clinical Professor of Pharmacy  
University of Colorado School of Pharmacy, Denver, CO

7/93 – 12/94 Adjoint Assistant Professor of Medicine  
1/95 – 11/01 Adjoint Associate Professor of Medicine  
11/01 – 9/05 Adjoint Professor of Medicine  
9/05 – 3/09 Clinical Professor of Medicine, Division of Infectious Diseases  
University of Colorado School of Medicine, Denver, CO

### III. Professional History

- 3/09 – present Professor, and Director  
Infectious Disease Pharmacokinetics Laboratory, College of Pharmacy,  
and Emerging Pathogens Institute, University of Florida, Gainesville, FL
- 2/11 – present Professor, College of Medicine, University of Florida

#### III a. Professional Licenses (Registered Pharmacist)

- 1982 State of Connecticut (#5884)  
1984 Commonwealth of Pennsylvania (inactive)  
1989 State of Colorado (#12831, inactive)  
2009 State of Florida Clinical Lab Technologist, LTD (#TNL 42669)

### IV. Honors and Awards

- 1980-present Rho Chi Honor Society  
1981 University of Connecticut Honor Scholar  
1987-1988 ACCP Infectious Disease Research Fellow  
2010 FCCP, Fellow of the American College of Clinical Pharmacy  
2014 UF Research Foundation Professor

### V. Professional Affiliations

- 1982-2004 American Society of Health Systems Pharmacists  
1986-present American College of Clinical Pharmacy  
1989-2003 Colorado Society of Hospital Pharmacists  
1990-present American Society of Microbiology  
1991-present Society of Infectious Disease Pharmacists  
1995-present International Union Against Tuberculosis and Lung Disease  
2004-present International Society of Antimicrobial Pharmacology  
2013-present National Tuberculosis Controllers Association

### VI. Professional Service and Committees

#### A. Institutional and Departmental Committees

- 2009 UF Clinical and Translational Science Institute (CTSI) Translational Science  
Advisory Committee (TSAC)  
2010-2015 COP Tenure and Promotion Committee (Chair 2013-2015)  
2011-2012 Facilities & Resources Sub-Committee  
2011-2013 Professionalism Committee  
2015 Prosper Review Committee  
2015-present Research Strategic Planning Task Force  
2010-present Numerous other recruitment and ad hoc committees

#### VI. Professional Service and Committees

##### B. National Service

- 2000-2009 Grant Reviewer for the U.S. Civilian Research and Development Foundations  
2006 - present NIH Committee on Guidelines for the Prevention and Treatment  
of Opportunistic Infections in Patients with HIV

2009 Participant, FDA Conference on Issues in the Design of Clinical Trials of Antimycobacterial Drugs for  
the Treatment of Tuberculosis. Silver Spring, MD, July 30-31, 2009

2013 – present ATS/CDC/IDSA/AAP TB Treatment Guidelines Revision

2014 – present American Thoracic Society (ATS) Project Committee: Setting a Prioritized Research  
Agenda for Nontuberculous Mycobacterial Infections

### C. International Service

2007 – present Organizing Committee, International Workshop on  
Clinical Pharmacology of Tuberculosis Drugs  
1<sup>st</sup> Workshop, Toronto, Ontario, Canada, May 15, 2008  
2<sup>nd</sup> Workshop, San Francisco, CA, September 11, 2009  
3<sup>rd</sup> Workshop, Boston, MA, September 11, 2010  
4<sup>th</sup> Workshop, Chicago, IL, September 16, 2011  
5<sup>th</sup> Workshop, San Francisco, CA, September 8, 2012  
6<sup>th</sup> Workshop, Denver, CO, September 9, 2013  
7<sup>th</sup> Workshop, Washington, DC, September 5, 2014  
8<sup>th</sup> Workshop, San Diego, CA, September 17, 2015  
9<sup>th</sup> Workshop, Liverpool, UK, to be held October 2016

2008 Participant, Workshop on Clinical Trials for Drug-Resistant Tuberculosis, Cambridge, MA, USA, 10-12 June 2008

1991-2015 Department of Health and Human Services (DHHS):  
The Food and Drug Administration  
The Center for Disease Control and Prevention  
(Ad hoc) AIDS Clinical Trials Group (ACTG)  
(Ad hoc) Community Programs for Clinical Research on AIDS (CPCRA)

Industry: Jacobus Pharmaceuticals, Dura Pharmaceuticals, Coretech,  
Hoechst Marion Roussel / Sanofi Aventis, Pharmacia / Pfizer, Tibotec, Otsuka

### VII. Patents

None. Methods for the determination of antimycobacterial drug concentrations remain proprietary information.

### VIII. Review and Referee Activities

#### Journal Referee:

##### Regular:

1990 - present Pharmacotherapy  
1997 - present International Journal of Tuberculosis and Lung Disease  
1997 - present Clinical Infectious Diseases  
1998 - present Antimicrobial Agents and Chemotherapy  
2001 - present Journal of Antimicrobial Chemotherapy

##### Occasional:

Annals of Pharmacotherapy, Journal of Infectious Disease Pharmacotherapy  
American Journal of Respiratory and Critical Care Medicine  
Journal of the American Medical Association, Drugs, Tubercle and Lung Disease, Tuberculosis  
New England Journal of Medicine, Chest, Clinical Pharmacokinetics  
Journal of Chromatography B, Biomedical Sciences and Applications  
American Journal of Medicine, The Lancet  
Journal of Pharmacy and Pharmacology, International Journal of Pharmaceutics  
British Journal of Pharmacology, Pharmaceutical Research,  
Chemotherapy, mBio, J Theoretical Biology, Thorax, Current Opinion in Pharmacology,  
Journal of Infectious Diseases, Pakistan Journal of Scientific and Industrial Research

**Editorial Board:**

**Study review: (occasional)**

1993 - present Grant Reviewer for the World Health Organization  
2000 - present Grant Reviewer for Ontario HIV Treatment Network  
2010 - present NIH

**IX. Teaching Activities**

2010 - present College of Pharmacy, University of Florida  
PharmD Lectures: Pharmacotherapy III and V, Infectious Diseases  
Graduate Lectures, WPPD and Masters Courses  
Undergraduate, professional, and graduate students in the lab

**Graduate Students**

Eric Egelund, Pharm.D. Ph.D. candidate 2010 – 2014  
Aline Barth, Pharm.D. (co-preceptor, Hartmut Derendorf, Ph.D.) Ph.D. candidate 2011 – 2014  
Abdullah Alsultan, Pharm.D. Ph.D. candidate 2012 – 2016  
Marc Tobias Heinrichs, B.S. (co-preceptor, Hartmut Derendorf, Ph.D.) Ph.D. candidate 2014 –

**Clinical Pharmacy Resident**

Shaun Berning, Pharm.D. June 1991 – May 1992  
Current: Associate Professor, University of Colorado College of Pharmacy

**Fellows / Research Associates**

Amy Bulpitt, B.S. Pharmacy, R.Ph. June 1996 to July 1997  
NIH RO1 AI37845 Research Associate  
Current: Pharmacist, Swedish Medical Center, Denver

Rocsanna Namdar, Pharm.D. June 1997 to July 1998  
NIH RO1 AI37845 Research Associate  
Current: Rocsanna Namdar, Pharm.D., FCCP, BCPS, CNS Medical Science Liaison,  
Allergan Medical Affairs – Neuroscience, Allergan Inc.

Rebecca Malone, Pharm.D. June 1997 to July 1999  
FDA Orphan Product Division FD-R-000812-01 Research Associate  
Current: Clinical Pharmacist, University of Arizona, Tucson, AZ

Barbara Auclair, Pharm.D. November 1998 to November 1999  
NIH RO1 AI37845 Research Associate  
Current: Pharmacist, Greenville, SC

Min Zhu, Ph.D. December 1999 to September 2000  
NIH RO1 AI37845 Research Associate  
Current: Scientific Director, Pharmacokinetics and Pharmacometrics Division of PKDM, Amgen, Thousand  
Oaks, CA

Bryan McGee, Pharm.D. September 2007 to September 2008  
CU HIV Training Grant  
Current: Senior Medical Science Liaison at Alexion Pharmaceuticals, Inc.

**IX a. Specialized Training**

March 2013 Intermediate PK/PD Modeling Methodology Using Phoenix WinNonlin  
January 2015 Advanced PK/PD Modeling Methodology Using Phoenix WinNonlin

**IX b. Annual Continuing Education**

All requirements met for Pharmacist's license since 1981  
All requirements met for University of Florida since 2009  
All requirements met for Florida Clinical Laboratory Technologist license since 2009

**X. Research Grants, Contracts, and Special Grants**

See attached spreadsheet from COP Research Support

**X a. Clinical Program Revenues**

Revenue for Laboratory Services:

The Infectious Disease Pharmacokinetics Laboratory

Founder and Director: Charles A. Peloquin, Pharm.D.

The IDPL is the nation's only reference laboratory specializing in therapeutic drug monitoring and interpretation for all of the antimycobacterial drugs, plus antifungal and anti-HIV drugs.

Total Gross Revenue:

University of Florida \$ 2,268,532

Fiscal Year 2015: \$381,899

Fiscal Year 2014: \$470,475

Fiscal Year 2013: \$438,134

Fiscal Year 2012: \$419,932

Fiscal Year 2011: \$424,492

Fiscal Year 2010: \$133,600

## XI. Bibliography

### A. Original research papers published in refereed journals (from 2009)

(total 141 papers: 20 first author, 39 senior author, 82 other)

88. Sung JC, Garcia-Contreras L, VerBerkmoes JL, **Peloquin CA**, Elbert KJ, Hickey AJ, Edwards DE. Dry powder nitroimidazopyran antibiotic PA-824 aerosol for inhalation. *Antimicrobial Agents and Chemotherapy* 2009; 53: 1338-1343. Epub 2009 Jan 12. PMID: 19139288
89. Holland DP, Hamilton CD, Weintrob AC, Engemann JJ, Fortenberry ER, **Peloquin CA**, Stout JE. Therapeutic drug monitoring in patients with tuberculosis and advanced human immunodeficiency virus infection. *Pharmacotherapy* 2009; 29: 503–510. PMID: 19397460
90. Sung JC, Garcia-Contreras L, VerBerkmoes JL, Padilla DJ, **Peloquin CA**, Elbert KJ, Hickey AJ, Edwards DE. Formulation and Pharmacokinetics of Self-Assembled Rifampicin Nanoparticle Systems for Pulmonary Delivery. *Pharmaceutical Research* 2009; 26: 1847-1855. Epub 2009 Apr 30. PMID: 19407933
91. Chideya S, Winston CA, **Peloquin CA**, Bradford WZ, Hopewell PC, Wells, CD, Reingold AL, Kenyon TA, Moeti TL, Tappero JW. Isoniazid, Rifampin, Ethambutol and Pyrazinamide Pharmacokinetics and Treatment Outcomes among a Predominantly HIV-Infected Cohort of Adults with Tuberculosis – Botswana. *Clin Infect Dis.* 2009; 48: 1685-1694. PMID: 19432554
92. McGee B, Dietze R, Hadad DJ, Molino LP, Maciel EL, Boom WH, Palaci M, Johnson JL, Peloquin CA. Population Pharmacokinetics of Linezolid in Adults with Pulmonary Tuberculosis. *Antimicrob Agents Chemother.* 2009; 53: 3981-3984. Epub 2009 Jun 29. PMID: 19564361
93. Almeida D, Nuernberger E, Tasneen R, Rosenthal I, Tyagi S, Williams K, Peloquin C, Grosset J. Paradoxical effect of isoniazid on the activity of the rifampin-pyrazinamide combination in the mouse model of tuberculosis. *Antimicrob Agents Chemother.* 2009; 53: 4178-4184. Epub 2009 Jul 20. PMID: 19620331
94. Barroso EC, Pinheiro VGF, Facanha MC, Carvalho MRD, Moura ME, Campelo CL, **Peloquin CA**, Guerrant RL, Lima AAM. Serum concentrations of rifampin, isoniazid, and intestinal absorption, permeability in patients with multidrug resistant tuberculosis. *American Journal of Tropical Medicine and Hygiene* 2009; 81: 332-329. PMID: 19635892
95. Ahmad Z, Klinkenberg KG, Pinn ML, Fraig MM, **Peloquin CA**, Bishai WR, Nuernberger EL, Grosset JG, Karakousis PC. Biphase Kill Curve of Isoniazid Reveals the Presence of Drug-Tolerant, Not Drug-Resistant, *Mycobacterium tuberculosis* in the Guinea Pig. *J Infect Dis.* 2009 Oct 1; 200: 1136-1143. Aug 17. [Epub ahead of print] PMID: 19686043
96. Boulanger C, Hollender E, Farrell K, Stambaugh JJ, Maasen D, Ashkin D, Symes S, Espinoza LA, Rivero RO, Graham JJ, **Peloquin CA**. Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis. *Clinical Infectious Diseases* 2009; 49: 1305-1311. PMID: 19807276
97. Luber A, Condoluci D, Slowinski P, Andrews M, Olson K, **Peloquin C**, Pappa K, Pakes G; for the COL104422 Study Team. Steady-state amprenavir and tenofovir pharmacokinetics after coadministration of unboosted or ritonavir-boosted fosamprenavir with tenofovir disoproxil fumarate in healthy volunteers. *HIV Med.* 2010 Mar;11(3):193-9. Epub 2009 Oct 23. PMID: 19863619

**A. Original research papers published in refereed journals (from 2009)**

98. Ahmad Z, Nuermberger EL, Tasneen R, Pinn ML, Williams KN, **Peloquin CA**, Grosset JH, Karakousis PC. Comparison of the 'Denver regimen' against acute tuberculosis in the mouse and guinea pig. *J Antimicrob Chemother.* 2010 Apr;65(4):729-34. Epub 2010 Jan 31. PMID: 20123722
99. Weinberg A, Forster-Harwood J, McFarland E, Pappas J, Davies J, Kinzie K, Barr E, Paul S, Salbenblatt C, Soda E, Vazquez A, **Peloquin CA**, Levin M. Kinetics and Determining Factors of the Virologic Response to Antiretrovirals During Pregnancy. *Infect Dis Obstet Gynecol.* 2009;2009:621780. Epub 2010 Jan 10. PMID: 20130816
100. Façanha MC, Gondim AM, Pinheiro VG, Barroso EC, Peloquin CA, Guerrant RL, Lima AA. Intestinal barrier function and serum concentrations of rifampin, isoniazid and pyrazinamide in patients with pulmonary tuberculosis. *Braz J Infect Dis.* 2009 Jun;13(3):210-7. PMID: 20191199
101. Weiner M, **Peloquin C**, Burman W, Luo CC, Engle M, Prihoda T, Mac Kenzie W, Bliven-Sizemore E, Johnson J, Vernon A for the Tuberculosis Trials Consortium. The effects of tuberculosis, race and human gene SLCO1B1 polymorphisms on rifampin concentrations. *Antimicrob Agents Chemother.* 2010 Jul 26. [Epub ahead of print] PMID: 20660695
102. Ahmad Z, Pinn ML, Nuermberger EL, **Peloquin CA**, Grosset JH, Karakousis PC. The potent bactericidal activity of streptomycin in the guinea pig model of tuberculosis ceases due to the presence of persisters. *J Antimicrob Chemother.* 2010 Aug 6. [Epub ahead of print] PMID: 20693172
103. Ahmad Z, **Peloquin CA**, Singh RP, Derendorf H, Tyagi S, Ginsberg A, Grosset JH, Nuermberger EL. PA-824 exhibits time-dependent activity in a murine model of tuberculosis. *Antimicrob Agents Chemother.* 2010 Oct 11. [Epub ahead of print] PMID: 20937781
104. De Groote MA, Gilliland JC, Wells CL, Brooks E, Woolhiser LK, Gruppo VR, **Peloquin CA**, Orme IM, Lenaerts A. Comparative studies evaluating mouse models used for efficacy testing of experimental drugs against *M. tuberculosis*. *Antimicrobial Agents and Chemotherapy* 2010 Dec 6. [Epub ahead of print]
105. Ahmad Z, Minkowski A, **Peloquin CA**, Williams K, Grosset JH, Nuermberger EL. Activity of the fluoroquinolone DC-159a in the initial and continuation treatment of murine tuberculosis. *Antimicrob Agents Chemother.* 2011 Jan 31. [Epub ahead of print]
106. Zhang M, Li SY, Rosenthal IM, Almeida DV, Ahmad Z, Converse PJ, **Peloquin CA**, Nuermberger EL, Grosset JH. Treatment of Tuberculosis with Rifamycin-containing Regimens in Immune Deficient Mice *Am J Respir Crit Care Med.* 2011 May 1;183(9):1254-61. Epub 2011 Feb 17. PMID: 21330452
107. Tasneen R, Li SY, **Peloquin CA**, Taylor D, Williams KN, Andries K, Mdluli KE, Nuermberger EL. Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis. *Antimicrob Agents Chemother.* 2011 Sep 19. [Epub ahead of print], print *Antimicrob Agents Chemother.* 2011; 55: 5485-5492.
108. Rhoades JA, Peterson YK, Zhu HJ, Appel DI, **Peloquin CA**, Markowitz JA. Prediction and in vitro evaluation of selected protease inhibitor antiviral drugs as inhibitors of carboxylesterase 1: a potential source of drug-drug interactions. *Pharmaceutical Research Pharm Res.* 2012; 29:972-82. Epub 2011 Dec 9. [Published online Dec 09, 2011]

**A. Original research papers published in refereed journals (from 2009)**

109. Williams K, Minkowski A, Amoabeng O, **Peloquin CA**, Taylor D, Andries K, Wallis WS, Mdluli KE, Nuermberger EL. Sterilizing activity of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis. *Antimicrob Agents Chemother.* 2012 Jun;56(6):3114-20. Epub 2012 Apr 2. PMID: 22470112
110. Tsuji BT, Brown T, Parasrampur R, Brazeau D, Forrest A, Kelchlin PA, Holden PN, **Peloquin CA**, Hanna D, Bulitta J. Front-Loaded Linezolid Regimens Result in Increased Killing and Suppression of the Accessory Gene Regulator System of *Staphylococcus aureus*. *Antimicrob Agents Chemother.* 2012 Jul;56(7):3712-9. Epub 2012 Apr 23. PMID: 22526313
111. Dutta NK, Illei PB, **Peloquin CA**, Pinn ML, Nuermberger EL and Karakousis PC. Rifapentine is not more active than rifampin against chronic tuberculosis in guinea pigs. *Antimicrob Agents Chemother.* 2012 Jul;56(7):3726-31. Epub 2012 Apr 30. PMID: 22547623
112. Rosenthal IM, Tasneen R, **Peloquin CA**, Zhang M, Almeida D, Mdluli KE, Karakousis PC, Grosset JH, Nuermberger EL. Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis. *Antimicrob Agents Chemother.* 2012 Aug;56(8):4331-40. doi: 10.1128/AAC.00912-12. Epub 2012 Jun 4. PMID: 22664964
113. Tsuji BT, Brown T, Bulitta J, Forrest A, Brazeau D, Kelchlin PA, Holden PN, **Peloquin CA**, Skerlos L, Hanna D. Pharmacodynamics of Early, High Dose Linezolid against Vancomycin-Resistant Enterococci (VRE) with Elevated MICs and Pre-Existing Genetic Mutations. *J Antimicrob Chemother.* 2012 Sep;67(9):2182-90. doi: 10.1093/jac/dks201. Epub 2012 Jun 8. PMID: 22685161
114. van Ingen J, Egelund EF\*\*, Levin A, Totten SE, Boeree MJ, Mouton JW, Aarnoutse RE, Heifets LB, **Peloquin CA**, Daley CL.. The Pharmacokinetics and Pharmacodynamics of Pulmonary Mycobacterium Avium Complex Disease Treatment. *Am J Respir Crit Care Med.* 2012 Sep 15;186(6):559-65. doi: 10.1164/rccm.201204-0682OC. Epub 2012 Jun 28. PMID: 22744719
115. Matthias KR, Nix DE, **Peloquin CA**, Graham ML. Poor Absorption of High-Dose Posaconazole in Pediatric Bone Marrow Transplant Patients. *Ann Pharmacother.* 2012 Sep;46(9):e22. doi: 10.1345/aph.1Q456. Epub 2012 Aug 7. PMID: 22872751
116. Glover TL, Goodin BR, Horgas AL, Kindler LL, King CB, Sibille K, **Peloquin CA**, Riley III, JR, Staud R, Bradley LA, Fillingim RB. Vitamin D, Race, and Pain. *Arthritis Rheum.* 2012 Dec;64(12):3926-35. doi: 10.1002/art.37687. PMID: 23135697
117. Dutta NK, Alsultan A, **Peloquin CA**, Karakousis PC. Preliminary pharmacokinetic study of repeated doses of rifampin and rifapentine in guinea pigs. *Antimicrob Agents Chemother.* 2013 Mar;57(3):1535-7. doi: 10.1128/AAC.01933-12. Epub 2013 Jan 7. PMID: 2329592
118. Egelund EF\*\*, Egelund TA, Ng JS, Wassil SK, **Peloquin CA**. Posaconazole pharmacokinetics in a 2-year-old boy with rhino-cerebral-orbital zygomycosis. *Pharmacotherapy.* 2013 Jan;33(1):e1-8. doi: 10.1002/phar.1172. PMID: 23307552



**A. Original research papers published in refereed journals (from 2009)**

119. Ahmad Z, Tyagi S, Minkowski A, **Peloquin CA**, Grosset JH, Nuermberger EL. Contribution of Moxifloxacin or Levofloxacin in Second-line Regimens with or without Continuation of Pyrazinamide in Murine Tuberculosis. *Am J Respir Crit Care Med*. 2013 Jul 1;188(1):97-102. doi: 10.1164/rccm.201212-2328OC. PMID: 23593945
120. Dutta NK, Alsultan A, Gniadek TJ, Belchis DA, Pinn ML, Mdluli KE, Nuermberger EL, **Peloquin CA**, Karakousis PC. Potent rifamycin-sparing regimen cures guinea pig tuberculosis as rapidly as the standard regimen. *Antimicrob Agents Chemother*. 2013 Aug;57(8):3910-6. doi: 10.1128/AAC.00761-13. Epub 2013 Jun 3. PMID: 23733473
121. Mpagama SG, Ndusilo N, Stroup S, Kumburu H, **Peloquin CA**, Gratz J, Moore JL, Houpt ER, Kibiki GS, Heysell SK Plasma drug activity in multidrug-resistant tuberculosis. *Antimicrob Agents Chemother*. 2014 Feb;58(2):782-8. doi: 10.1128/AAC.01549-13. Epub 2013 Nov 18. PMID: 24247125
122. Weiner M, Egelund EF, Engle M, Kiser M, Prihoda TJ, Gelfond JAL, Mac Kenzie W, **Peloquin CA**. The Pharmacokinetic Interaction Between Raltegravir and Rifapentine in Healthy Volunteers. *J Antimicrob Chemother*. 2014 Apr;69(4):1079-85. doi: 10.1093/jac/dkt483. Epub 2013 Dec 15. PMID: 24343893
123. Weiner M, Savic RM, Mac Kenzie WR, Wing D, **Peloquin CA**, Engle M, Bliven E, Borisov A, Prihoda TJ, Gelfond J, Wing R, Abdel-Rahman SM, Kearns GL, Burman WJ, Sterling TR, Villarino ME Rifapentine Pharmacokinetics and Tolerability in Children and Adults Treated Once Weekly with Rifapentine and Isoniazid for Latent Tuberculosis Infection. *Journal of the Pediatric Infectious Diseases Society* pp. 1-14, 2014. DOI:10.1093/jpids/pit077
124. Kwara A, Cao L, Poethke P, Kurpewski KT, Mahjoub B, Court MH, **Peloquin CA**. Factors Associated with Variability in Rifampin Plasma Pharmacokinetics and the Relationship between Rifampin Concentrations and Drug Interactions with Efavirenz. *Pharmacotherapy*. 2014 Mar;34(3):265-71. doi: 10.1002/phar.1388. Epub 2014 Jan 13. PMID: 24420746
125. Brock AP, Isaza R, Egelund EF, Hunter RP, and **Peloquin CA**. The Pharmacokinetics of a Single Oral or Rectal Dose of Concurrently Administered Isoniazid, Rifampin, Pyrazinamide, and Ethambutol in Asian Elephants (*Elephas maximus*). *J Vet Pharmacol Ther*. 2014 Mar 29. doi: 10.1111/jvp.12119. [Epub ahead of print] PMID: 24684601
126. Egelund EF, Weiner W, Singh Rp, Prihoda TJ, Derendorf H, Mac Kenzie WR, and **Peloquin CA**. Protein Binding of Rifapentine and the 25-Desacetyl Metabolite in Patients with Pulmonary Tuberculosis. *Antimicrob Agents Chemother*. 2014 May 19. pii: AAC.01730-13. [Epub ahead of print] PMID: 24841270
127. Drusano GL, Neely M, Van Guilder M, Schumitzky A, Brown D, Fikes S, **Peloquin C**, Louie A. Analysis of combination drug therapy to develop regimens with shortened duration of treatment for tuberculosis. *PLoS One*. 2014 Jul 8;9(7):e101311. doi: 10.1371/journal.pone.0101311. eCollection 2014. PMID: 25003557

**A. Original research papers published in refereed journals (from 2009)**

128. Egelund EF, Isaza R, Brock AP, Alsultan A, An G, **Peloquin CA**. Population Pharmacokinetics of Rifampin in the treatment of Mycobacterium tuberculosis in Asian Elephants. *J. Vet. Pharmacol. Therap.* doi: 10.1111/jvp.12156 [Sept 2014]
129. Kempker R, Barth B, Vashakidze S, Nikolaishvili K, Sabulua I, Tukvadze N, Bablishvili N, Singh R, Guarner J, Derendorf H, **Peloquin CA**, Blumberg H. Cavitory Penetration of Levofloxacin among Patients with Multidrug-Resistant Tuberculosis. *Antimicrob Agents Chemother.* 2015 Mar 16. pii: AAC.00379-15. [Epub ahead of print] PMID: 25779583
130. Tucker L, Higgins T, Egelund EF, Zou B, Vijayan V, and **Peloquin CA**. Voriconazole Monitoring in Children with Invasive Fungal Infections. *The Journal of Pediatric Pharmacology and Therapeutics* 2015; 20: 17-23. doi: 10.5863/1551-6776-20.1.17. PMID: 25859166
131. Heysell SK, Moore JL, **Peloquin CA**, Ashkin D, Houpt ER. Outcomes and use of therapeutic drug monitoring in multidrug-resistant TB patients treated in Virginia, 2009-2014. *Tuberculosis and Respiratory Disease.* 2015; 78: 78-84. doi: 10.4046/trd.2015.78.2.78. Epub 2015 Apr 2. PMID: 25861340
132. Alsultan A, An G, **Peloquin CA**. Limited Sampling Strategy and Target Attainment Analysis for Levofloxacin in Patients with Tuberculosis. *Antimicrob Agents Chemother.* 2015 Apr 13. pii: AAC.00341-15. [Epub ahead of print] PMID: 25870068
133. Kwara A, Enimil A, Gillani FS, Yang H, Sarfo AM, Dompok A, Ortsin A, Osei-Tutu L, Kwarteng Owusu S, Wiesner L, Norman J, Kurpewski J, Peloquin CA, Ansong D, Antwi S. Pharmacokinetics of First-Line Antituberculosis Drugs Using WHO Revised Dosage in Children With Tuberculosis With and Without HIV Coinfection. *J Pediatric Infect Dis Soc.* 2015 May 26. pii: piv035. [Epub ahead of print] PMID: 26407268
134. Long R, Barrie J, **Peloquin CA**. Therapeutic drug monitoring and the conservative management of chronic tuberculous empyema: case report and review of the literature. *BMC Infect Dis.* 2015 Aug 12;15:327. doi: 10.1186/s12879-015-1093-7. PMID: 26265445
135. Mase SR, Jereb JA, Gonzalez D, Martin F, Daley CL, Fred D, Loeffler A, Menon L, Morris SB, Brostrom R, Chorba T, **Peloquin CA**. Pharmacokinetics and Dosing of Levofloxacin in Children Treated for Active or Latent Multidrug-Resistant Tuberculosis, Federated States of Micronesia and Republic of the Marshall Islands. *Pediatr Infect Dis J.* 2015 Dec 10. [Epub ahead of print] PMID: 26658531
136. Hennig S, Svensson EM, Niebecker R, Fourie PB, Weiner MH, Bonora S, **Peloquin CA**, Gallicano K, Flexner C, Pym A, Vis P, Olliaro PL, McIlleron H, Karlsson MO. Population pharmacokinetic drug-drug interaction pooled analysis of existing data for rifabutin and HIV PIs. *J Antimicrob Chemother.* 2016 Jan 31. pii: dkv470. [Epub ahead of print] PMID: 26832753
137. Bannietts N, Sharma R, Hand I, **Peloquin CA**, Kohlhoff S, Hammerschlag MR. Steady-state pharmacokinetics of oral linezolid suspension in a premature infant with osteomyelitis. *J Antimicrob Chemother.* 2016 Feb 6. pii: dkv507. [Epub ahead of print] PMID: 26851607

**A. Original research papers published in refereed journals (from 2009)**

138. Hope WW, Walsh TJ, Goodwin J, **Peloquin CA**, Howard A, Kurtzberg J, Mendizabal A, Confer DL, Bulitta J, Baden LR, Neely MN, Wingard JR for the Blood and Marrow Transplant Clinical Trials Network. Voriconazole pharmacokinetics following HSCT: results from the BMT CTN 0101 trial. *J Antimicrob Chemother.* 2016 Apr 27. pii: dkw127. [Epub ahead of print] PMID: 27121401
139. Zentner I, Schlecht HP, Khensouvann L, Tamuhla N, Kutzler M, Ivaturi V, Pasipanodya JG, Gumbo T, **Peloquin CA**, Bisson GP, Vinnard C. Urine colorimetry to detect Low rifampin exposure during tuberculosis therapy: a proof-of-concept study. *BMC Infect Dis.* 2016 Jun 1;16(1):242. doi: 10.1186/s12879-016-1576-1. PMID: 27250739
140. Furin JJ, Du Bois J, van Brakel E, Chheng P, Venter A, **Peloquin CA**, Alsultan A, Thiel B, Debanne SM, Boom WH, Diacon AH, Johnson JL. Early Bactericidal Activity of AZD5847 in Pulmonary Tuberculosis. *Antimicrob Agents Chemother.* 2016 Aug 22. pii: AAC.01163-16. [Epub ahead of print] PMID: 27550361
141. Milstein M, Lecca L, **Peloquin C**, Mitchison D, Seung K, Pagano M, Coleman D, Osso E, Coit J, Vargas Vasquez DE, Sanchez Garavito E, Calderon R, Contreras C, Davies G, Mitnick CD. Evaluation of high-dose rifampin in patients with new, smear-positive tuberculosis (HIRIF): study protocol for a randomized controlled trial. *BMC Infect Dis.* 2016 Aug 27;16(1):453. doi: 10.1186/s12879-016-1790-x. PMID: 27567500

**XI. B. Review papers published in refereed journals (from 2009)**

(total 34 papers: 12 first author, 12 senior author, 10 other)

22. Mitnick CD, McGee B, **Peloquin CA**. Tuberculosis pharmacotherapy: strategies to optimize patient care. *Expert Opin Pharmacother* 2009; 10: 381-401. PMID: 19191677
23. Sabarinath SN, Wu B, **Peloquin CA**, Derendorf H. Pharmacometrics in dose finding of anti-retroviral and anti-tubercular drugs. *Infect Disord Drug Targets*. 2011 Apr 1;11(2):157-66. PMID: 21406049
24. Egelund EF, Barth AB, **Peloquin CA**. Population Pharmacokinetics and its role in Anti-tuberculosis Drug Development & Optimization of Treatment *Curr Pharm Des*. 2011 Aug 12. [Epub ahead of print] PMID: 21834766
25. Seddon JA, Hesselting AC, Marais BJ, McIlleron H, **Peloquin CA**, Donald PR, Schaaf HS. Paediatric use of second-line tuberculosis agents: a review. *Tuberculosis (Edinb)*. 2011 Nov 24. [Epub ahead of print] PMID: 22118883
26. Lauzardo M, **Peloquin CA**. Anti-tuberculosis Therapy for 2012 and Beyond. *Expert Opin Pharmacother*. 2012; 13: 511-26.
27. Srivastava S, **Peloquin CA**, Sotgiu G and Migliori GB. Therapeutic Drug Management: is it the future of MDR-TB treatment? Letter. *European Respiratory Journal* 2013; 42:1449-1453.
28. Obeng AO, Egelund EF, Alsultan A, **Peloquin CA**, Johnson JA. CYP2C19 Polymorphisms and Voriconazole Therapy: Are We Ready for Clinical Implementation of Pharmacogenomics? *Pharmacotherapy*. 2014 Feb 7. doi: 10.1002/phar.1400. [Epub ahead of print] PMID: 24510446
29. Alsultan A, Peloquin CA. Therapeutic Drug Monitoring in the Treatment of Tuberculosis, an update. *Drugs*. 2014 May 21. [Epub ahead of print] PMID: 24846578
30. Egelund EF, Fennelly KP, **Peloquin CA**. Medications and Monitoring in Nontuberculous Mycobacteria Infections. *Clin Chest Med*. 2015 Mar;36(1):55-66. doi: 10.1016/j.ccm.2014.11.001. Epub 2014 Dec 18.. PMID: 25676519
31. Egelund EF, Alsultan A, **Peloquin CA**. Optimizing the clinical pharmacology of tuberculosis medications. *Clin Pharmacol Ther*. 2015 Jul 2. doi: 10.1002/cpt.180. [Epub ahead of print] PMID: 26138226
32. Veringa A, Sturkenboom MGG, Dekkers BGJ, Koster RA, Roberts JA, **Peloquin CA**, Touw DJ, Alffenaar JWC. LC-MS/MS for Therapeutic Drug Monitoring of anti-infective drugs. *Trends in Analytical Chemistry*. 2016, doi: 10.1016/j.trac.2015.11.026
33. Lauzardo M, Peloquin CA. Tuberculosis therapy for 2016 and beyond. *Expert Opin Pharmacother*. 2016 Aug 19:1-14. [Epub ahead of print]
34. Rifapentine for the treatment of latent tuberculosis. Egelund EF, Peloquin CA. *Expert Rev Clin Pharmacol*. 2016 Aug 22:1-9. [Epub ahead of print] PMID: 27545595

**XI. C. Book Chapters (from 2009)**

(total 41 chapters: 19 first author, 21 senior author, 1 other)

28. Namdar R, **Peloquin CA**. Ethionamide. In Yu VL, Edwards G, McKinnon PS, Peloquin C, Morse GD, editors. Antimicrobial Chemotherapy and Vaccines Vol II: Antimicrobial Agents 2010. Pittsburgh; Esun Technologies, LLC. Available from: <http://www.antimicrobe.org/index.asp>
29. **Peloquin CA**, Namdar R. Tuberculosis. In Chisholm-Burns MA, Wells BG, Schwinghammer TL, Malone PM, Kolesar JM, Rotschafer JC, DiPiro JT Eds. Pharmacotherapy: principles and practice, 2<sup>nd</sup> Ed. McGraw Hill, New York, 2010. p 1253-1263.
30. **Peloquin CA**, Namdar R. Tuberculosis. In DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, Eds. Pharmacotherapy: A pathophysiologic approach, 8th ed. McGraw Hill, New York, 2011 p 1931-1949.
31. Egelund EF, **Peloquin CA**. Current Issues in Tuberculosis Pharmacokinetics. In Donald PR, van Helden PD, Eds. Antituberculosis Chemotherapy. Prog Respir Res. Basel, Karger, 2011, vol 40, pp 153–160.
32. Namdar R, **Peloquin CA**. Drugs for Tuberculosis. In Piscitelli SC, Rodvold KA, Pai MP Eds. Drug Interactions in Infectious Diseases, 3<sup>rd</sup> Edition. Humana Press, c/o Springer Science+Business Media, LLC, 233 Spring Street, New York, NY, 2011, p 401-424.
33. Barth AB, Egelund EF, **Peloquin CA**. Rifamycin Use in HIV-infected Patients with Tuberculosis. Yi-Wei Tang, Ed. Recent Translational Research in HIV/AIDS. InTech, Rijeka, Croatia. 2011. ISBN 978-953-307-719-2
34. Namdar R, **Peloquin CA**. Tuberculosis. In PSAP VII Infectious Diseases, ACCP, Lenexa, KS 2012, p. 53-74.
35. **Peloquin CA**, Namdar R. Tuberculosis. In Chisholm-Burns MA, Wells BG, Schwinghammer TL, Malone PM, Kolesar JM, Rotschafer JC, DiPiro JT Eds. Pharmacotherapy: principles and practice, 3<sup>rd</sup> Ed. McGraw Hill, New York, 2013, p 1315 – 1327.
36. Namdar R, Lauzardo M, **Peloquin CA**. Tuberculosis. In DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, Eds. Pharmacotherapy: A pathophysiologic approach, 9th ed. McGraw Hill, New York, 2014, p 1787-1806.
37. Abdullah Alsultan, **Peloquin CA**. Clinical pharmacology of the anti-tuberculosis drugs. Davies PDO, Gordon SB, Davies G, Ed. Clinical Tuberculosis, 5th Ed. CRC Press, Boca Raton, 2014, p 209 – 228.
38. **Peloquin CA**. Pharmacometrics and Tuberculosis. In Derendorf H and Schmidt S, Eds. Applied Pharmacometrics. Springer New York, 2014, p 325-348.
39. Egelund EF, **Peloquin CA**. Antimycobacterial Drugs. In Lippincott’s Illustrated Reviews: Pharmacology, 6<sup>th</sup> Edition. Wolters Kluwer 2015, p 525-534.

**XI. C. Book Chapters (from 2009)**

40. Barth AB, Egelund EF, **Peloquin CA**. Pharmacokinetics and Pharmacodynamics of the Tuberculosis Drugs. In John C. Rotschafer, David R. Andes, Keith A. Rodvold, Eds. Antibiotic Pharmacodynamics. Humana Press, Methods in Pharmacology and Toxicology, Springer Science+Business Media New York, 2016. ISBN: 978-1-4939-3321-1 (Print) 978-1-4939-3323-5 (Online) p 385-414.
41. Namdar R., Lauzardo M, **Peloquin CA**. Tuberculosis. In Chisholm-Burns MA, Schwinghammer TL, Wells BG, Malone PM, Rotschafer JC, DiPiro JT, Kolesar JM, Eds. *Pharmacotherapy: principles and practice*, 4th Edition. McGraw Hill, New York, 2016, p 1123-1134.

**XI. D. Other Publications (from 2009)**

(total 34 papers: 26 first author, 6 senior author, 2 other)

28. **Peloquin C.** Aminoglycoside nephrotoxicity. (letter) *Antimicrob Agents Chemother.* 2010; 54: 2750-2751. PMID: 20480959

29. Stein GE, Smith CL, **Peloquin CA**, Mosher B, Dybas L, Kepros JP. Bile and Gallbladder Tissue Concentrations of Moxifloxacin in Patients with Acute Cholecystitis. *Ann Pharmacother.* 2010 Jun 15. [Epub ahead of print] PMID: 20551298

30. **Peloquin CA** Pharmacokinetic Mismatch of Tuberculosis Drugs. *Antimicrob. Agents Chemother.* 2012, 56:1666.

31. Egelund EF\*\*, **Peloquin CA.** Pharmacokinetic variability and TB treatment outcomes, including acquired drug resistance. Invited Editorial. *Clin Infect Dis.* 2012 Jul;55(2):178-9. doi: 10.1093/cid/cis366. Epub 2012 Mar 30. PMID: 22467672

32. Nuermberger EL, Rosenthal IM, Tasneen R, **Peloquin CA**, Mdluli KE, Karakousis PC, Grosset JH. Reply to "contradictory results with high-dosage rifamycin in mice and humans". *Antimicrob Agents Chemother.* 2013 Feb;57(2):1104-5. doi: 10.1128/AAC.02216-12. PMID: 23341430

33. Egelund EF, Mohamed M, Fennelly KP, **Peloquin CA.** Concomitant Use of Carbamazepine and Rifampin in a Patient with Mycobacterium Avium Complex and Seizure Disorder. *Journal of Pharmacy Technology* 2014; 30: 93-96.

34. **Peloquin CA.** Pharmacometrics in Tuberculosis. In Derendorf H and Schmidt S, Eds. *Henry Stewart Talks.* [http://hstalks.com/main/view\\_talk.php?t=2953&r=494&c=252](http://hstalks.com/main/view_talk.php?t=2953&r=494&c=252) December 2014

**XI. E. Abstracts (from 2009)**

(total 133 abstracts; 27 first author, 29 senior author, 77 other)

74. Weiner M, **Peloquin C**, Burman W, Luo CC, Engle M, Prihoda T, Mac Kenzie W, Bliven E, Johnson J, Vernon A for the Tuberculosis Trials Consortium. The effects of tuberculosis infection, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations. Abstract 1, 2nd International Workshop on Clinical Pharmacology of Tuberculosis Drugs, San Francisco, CA, September 11, 2009.
75. Ahmad Z, **Peloquin C**, Tyagi S, Grosset JH, Nuermberger EL. PA-824 has time-dependent bactericidal activity in a murine model of tuberculosis. Abstract 4, 2nd International Workshop on Clinical Pharmacology of Tuberculosis Drugs, San Francisco, CA, September 11, 2009.
76. **Peloquin C**. PK-PD mismatch in TB drug regimens. Abstract 12, 2nd International Workshop on Clinical Pharmacology of Tuberculosis Drugs, San Francisco, CA, September 11, 2009.
77. Almeida D, Nuermberger EL, Tasneen R, Rosenthal I, Tyagi S, **Peloquin C**, Grosset JH. Paradoxical effect of isoniazid on the activity of the rifampin-pyrazinamide combination in the mouse model of tuberculosis. 2nd International Workshop on Clinical Pharmacology of Tuberculosis Drugs, San Francisco, CA, September 11, 2009.
78. Ahmad Z, **Peloquin C**, Tyagi S., J.H. Grosset., E. L. Nuermberger. Pa-824 Exhibits Time-Dependent Bactericidal Activity in a Murine Tuberculosis Model. 49<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy (A1-607), San Francisco, CA, September 12-15, 2009.
79. Curtis L. Smith, Gary E. Stein, Benjamin Mosher, **Charles Peloquin**, Leslie A. Dybas, and John P. Kepros. Bile and gallbladder tissue concentrations of moxifloxacin in patients with infectious cholecystitis for presentation at the 2010 Spring Practice and Research Forum (April 23-27), Charlotte, NC.
80. Ahmad Z, **Peloquin CA**, Minkowski A, Grosset JH and Nuermberger EL. The anti-tuberculous activity of pyrazinamide is driven by AUC/MIC in murine tuberculosis. 3<sup>rd</sup> International Workshop on Clinical Pharmacology of Tuberculosis Drugs, Boston, MA, Sep. 11, 2010.
81. Ahmad ., **Peloquin CA**, Minkowski A, Ginsberg A, Grosset JH and Nuermberger EL. PA-824 exhibits time-dependent bactericidal activity against persisting Mycobacterium tuberculosis. 3<sup>rd</sup> International Workshop on Clinical Pharmacology of Tuberculosis Drugs, Boston, MA, Sep. 11, 2010.
82. Ahmad Z, Pinn ML, Tyagi S, **Peloquin CA**, Nuermberger EL, Grosset JH, and Karakousis PC. Towards a guinea pig model for preclinical TB drug testing. 3<sup>rd</sup> International Workshop on Clinical Pharmacology of Tuberculosis Drugs, Boston, MA, Sep. 11, 2010.
83. **Peloquin C**, Weiner M, Engel M, Johnson H, Nsubuga P, Bliven E, Padayatchi N, Mthethwa T, MacKenzie W. Pharmacokinetics of rifapentine in TB patients receiving 600 mg daily. 3<sup>rd</sup> International Workshop on Clinical Pharmacology of Tuberculosis Drugs, Boston, MA, Sep. 11, 2010.
84. **Peloquin C**, Jereb J, Daley C, Fred D, Mase S. The pharmacokinetics of moxifloxacin in MDR TB contacts in the Federated States of Micronesia. 3<sup>rd</sup> International Workshop on Clinical Pharmacology of Tuberculosis Drugs, Boston, MA, Sep. 11, 2010.



## XI. E. Abstracts

85. **Peloquin C**, Jereb J, Daley C, Fred D, Mase S. The pharmacokinetics of levofloxacin in MDR TB contacts in the Federated States of Micronesia. 3<sup>rd</sup> International Workshop on Clinical Pharmacology of Tuberculosis Drugs, Boston, MA, Sep. 11, 2010.

86. Ahmad Z, Pinn M, Tyagi S, **Peloquin C**, Nuermberger E, Grosset J, Karakousis PC. Do Caseating Granulomas Interfere with the Sterilizing Activity of the Standard Antituberculous Regimen? 50<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, Sep. 12-15, 2010. Abstract B-2010.

87. Ahmad Z., **Peloquin CA**, Minkowski A., Grosset JH and Nuermberger EL. The anti-tuberculous activity of pyrazinamide is driven by AUC/MIC in murine tuberculosis. 50<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, Sep. 12-15, 2010.

88. E. Nuermberger, Z. Ahmad, Tyagi S., Ginsberg A, J.H. Grosset, **Peloquin C**. Pharmacodynamics of PA-824 activity in murine TB. IUATLD Berlin November 11-15 2010.

89. Jenna A. Rhoades, Hao-Jie Zhu, David I. Appel, Yuri K. Peterson, **Charles A. Peloquin** and John S. Markowitz. An *in-vitro* Evaluation of Protease Inhibitors on Carboxylesterase 1: A Potential Source of Drug-Drug Interactions. 24<sup>th</sup> Annual Research Showcase and Awards Recognition Day, February 17<sup>th</sup>, 2011

90. M. Weiner, **C. Peloquin**, E. Egelund, M. Engle, E. Bliven-Sizemore, W. R. Mac Kenzie, J. L. Johnson, P. Nsubuga, T. J. Prihoda, S. Dorman, W. J. Burman. Rifapentine Exposure In A Trial Of Daily Rifapentine Compared To Rifampin During The Intensive Phase Of TB Treatment. American Thoracic Society 2011 International Conference, May 13-18, 2011, Denver, Colorado

91. J.H.E. Grosset, M. Zhang, S.-Y. Li, **C. Peloquin**, D. Almeida, S. Tyagi, P. Converse, E.L. Nuermberger. In Contrast To Isoniazid, Ethambutol Does Not Antagonize The Rifampin - Pyrazinamide Combination. American Thoracic Society 2011 International Conference, May 13-18, 2011, Denver, Colorado

92. J. van Ingen, S. Totten, L.B. Heifets, **C. Peloquin**, C. L. Daley. Drug Susceptibility Testing And Pharmacokinetics Question Current Treatment Regimens In Mycobacterium Simiae Complex Disease. American Thoracic Society 2011 International Conference, May 13-18, 2011, Denver, Colorado

93. S. R. Mase, J. Jereb, C.L. Daley, D. Fred, A. Loeffler, **C. Peloquin**. Pharmacokinetics Of Levofloxacin In Pediatric Mdr Tb Cases And Contacts, Federated States Of Micronesia. American Thoracic Society 2011 International Conference, May 13-18, 2011, Denver, Colorado

94. S. R. Mase, J. Jereb, C. L. Daley, D. Fred, A. Loeffler, **C. Peloquin**. The Pharmacokinetics Of Moxifloxacin In Mdr Tb Cases And Contacts, Federated States Of Micronesia. American Thoracic Society 2011 International Conference, May 13-18, 2011, Denver, Colorado

95. J. van Ingen, A. Levin, S. Totten, L. B. Heifets, **C. Peloquin**, C. L. Daley. Pharmacokinetics And Drug Susceptibility Testing Imply Limited Activity Of Current Regimens For Mycobacterium Avium Complex Disease. American Thoracic Society 2011 International Conference, May 13-18, 2011, Denver, Colorado

## XI. E. Abstracts

96. Glover, T. L., Goodin, B. R., Kindler, L. L., King, C. B., Sibille, K., Horgas, A. L., **Peloquin, C**, Riley, III, J. R., Staud, R., Bradley, L. A., & Fillingim, R. B. (2011, May). Vitamin D deficiency as a mediator of ethnic differences in experimental pain: preliminary findings. Poster session to be presented at the meeting of the American Pain Society, May 18-21, 2011, Austin, TX.
97. Barth AB, Singh RP, Egelund EF, Ahmad Z, Nuermberger EL, **Peloquin CA**, Derendorf H. Exploratory pharmacokinetics – pharmacodynamics (PK-PD) target attainment analysis of PA-824. 4<sup>th</sup> International Workshop on Clinical Pharmacology of Tuberculosis Drugs, Chicago, IL, Sep. 16, 2011.
98. Nuermberger EL, Tanseen R, Li S, **Peloquin C**, Andries K, Mdluli K, Grosset J. Novel TMC-207-containing regimens have sterilizing activity in murine tuberculosis. 4<sup>th</sup> International Workshop on Clinical Pharmacology of Tuberculosis Drugs, Chicago, IL, Sep. 16, 2011.
99. **Peloquin C**, Weiner M, Bliven-Sizemore E, Egelund E, Engle M, Johnson J, Nsubuga P, MacKenzie WH. Modeling the pharmacokinetics of rifapentine in TB patients receiving 10 mg/kg daily. 4<sup>th</sup> International Workshop on Clinical Pharmacology of Tuberculosis Drugs, Chicago, IL, Sep. 16, 2011.
100. Marc Weiner, **Charles Peloquin**, Melissa Engle, Eric Egelund, Thomas Prihoda, William Mac Kenzie. The Pharmacokinetic Interaction Between Raltegravir and Rifapentine in Healthy Volunteers. 1th Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, WA, March 5-8, 2012.
101. M Degroote; J Gilliland; E Brooks; E Driver; R Basaraba; **C Peloquin**; I Orme; A Lenaerts. Evaluation of Linezolid in Mice Infected with Mycobacterium tuberculosis. Drug Resistance and Persistence in Tuberculosis, Kampala, Uganda, May 13 - May 18, 2012
102. S. R. Mase, J. Jereb, F. Martin, C. L. Daley, D. Fred, K. Briand, A. Loeffler, S. Bamrah, R. Brostrom, **C. Peloquin**, T. Chorba. Pharmacokinetics Studies of Levofloxacin in Children Treated for, or Exposed to, Multidrug-Resistant Tuberculosis — United States Affiliated Pacific Islands, 2010–2011. American Thoracic Society 2012 International Conference, May 18-23, 2012, San Francisco, CA
103. R.M. Savic, M. Weiner, W. Mac Kenzie, E. Bliven-Sizemore, **C.A. Peloquin**, K. Dooley, S.M. Abdel-Rahman, G.L. Kearns, W. Burman, T.R. Sterling, M.E. Villarino, and the Tuberculosis Trials Consortium. Population pharmacokinetics of once weekly rifapentine in children and adults. 5th International workshop on Clinical Pharmacology of TB Drugs, San Francisco, CA, USA, 8 September 2012
104. M. Weiner, R. Savic, D. Wing, W.R. Mac Kenzie, **C.A. Peloquin**, M. Engle, E. Bliven, A. Borisov, S.M. Abdel-Rahman, G.L. Kearns, W. Burman, T.R. Sterling, M.E. Villarino and the Tuberculosis Trials Consortium Study 26PK Group. Rifapentine Pharmacokinetics and Tolerability in Children and Adults Treated Once Weekly with Rifapentine/Isoniazid for Latent Tuberculosis Infection. 5th International workshop on Clinical Pharmacology of TB Drugs, San Francisco, CA, USA, 8 September 2012.
105. Pinn ML, Dutta NK, Sultan A, **Peloquin CA** and Karakousis PC. Comparative pharmacokinetics of repeated doses of rifampin and rifapentine in guinea pigs. Host Response in Tuberculosis, January, 2013• British Columbia, Canada.

## XI. E. Abstracts

106. Barth A, Singh R, Brull N, Reljac K, Klopp-Schulze L, **Peloquin C**, Derendorf, H. PK-PD Evaluation of Levofloxacin in vitro- Preliminary Data. Presented during the 26th College of Pharmacy Annual Research Showcase, Gainesville, FL. Feb/2013
107. Eric F. Egelund, R.P. Singh, Behrang Mahjoub, Hartmut Derendorf, Marc Weiner, **Charles A. Peloquin**. Protein Binding of Rifapentine and Its Metabolite, 25-desacetyl Rifapentine, in Patients with Pulmonary Tuberculosis. Emerging Pathogens Institute, University of Florida. Gainesville, FL. February 2013.
108. Daniel Gonzalez, Sundari Mase, John Jereb, F.S. Martin, Charles Daley, Dorina Fred, K. Briand, Ann Loeffler, Sapna Bamrah, K. Powell, Richard Brostrom, Terry Chorba, **Charles Peloquin**. Population Pharmacokinetics of Levofloxacin in Children Treated for, or Exposed to, Multidrug Resistant Tuberculosis in the Federated States of Micronesia and Republic of Marshall Islands. American Conference on Pharmacometrics, May 12-15, 2013 in Fort Lauderdale, FL
109. Abdullah Alsultan, Kelly E. Dooley, Marc Weiner, William Whitworth, William R. Mac Kenzie, **Charles A. Peloquin** and the Tuberculosis Trials Consortium. Population Pharmacokinetics of Pyrazinamide in Patients with Tuberculosis. American Conference on Pharmacometrics, May 12-15, 2013 in Fort Lauderdale, FL
110. Dutta NK, Belchis D, **Peloquin C**, Nuernberger EL, Mdluli K and Karakousis PC. Dramatic efficacy of the novel three-drug regimen PaMZ (PA-824/moxifloxacin/pyrazinamide) against chronic tuberculosis infection in guinea pigs. American Thoracic Society International Conference. May 17, 2013• Philadelphia, USA.
111. Aline Barth, Ravi Singh, **Charles Peloquin** and Hartmut Derendorf. Microdialysis as a tool to measure antimicrobials in the lung tissue – in vivo and ex vivo considerations. 7th Microdialysis Symposium - Université de Poitiers, France, May 23-24, 2013.
112. Awewura Kwara, Margaret Lartey, Ernest Kenu, Behrang Mahjoub, **Charles Peloquin**. Isoniazid, rifampicin and pyrazinamide pharmacokinetics in Ghanaian HIV/Tuberculosis Co-infected patients. 44<sup>th</sup> Union World Conference on Lung Health in Paris, France, November 2, 2013
113. D. Gonzalez, S. Mase, J. Jereb, F. Martin, C. Daley, D. Fred, K. Briand, A. Loeffler, T. Chorba, **C. Peloquin**. Population pharmacokinetics of levofloxacin in children treated for multidrug resistant tuberculosis. 6<sup>th</sup> International Workshop on Clinical Pharmacology of TB drugs, Denver, CO, Sept 9, 2013.
114. A. Alsultan, K. Dooley, M. Weiner, W. Whitworth, W. Mac Kenzie, **C. Peloquin**. Clinical Pharmacokinetics of Pyrazinamide in Patients with Tuberculosis. 6<sup>th</sup> International Workshop on Clinical Pharmacology of TB drugs, Denver, CO, Sept 9, 2013.
115. Savic RM, Weiner M, MacKenzie W, Helig C, Dooley K, Engle M, Nsubuga P, Phan H, **Peloquin C**, Dorman S. PK PD analysis of rifapentine in patients during intensive phase treatment for tuberculosis from Tuberculosis Trial Consortium Studies 29 and 29X. 6<sup>th</sup> International Workshop on Clinical Pharmacology of TB drugs, Denver, CO, Sept 9, 2013.

## XI. E. Abstracts

116. Brock, AP, Isaza R, Egelund, EF, Hunter, **Peloquin CA**. Pharmacokinetics of a single oral or rectal dose of concurrently administered isoniazid, rifampin, pyrazinamide and ethambutol in Asian elephants (*Elephas maximus*) 45th American Association of Zoo Veterinarian Annual Conference, Sept 28-Oct 4, 2013, Salt Lake City, UT.
117. Barth A, Singh R, May J, Johnson J, Prieto E, Isaza R, Kempker R, **Peloquin C**, Derendorf H. Levofloxacin Dose Optimization for Multidrug Resistant Tuberculosis Based on Lung Microdialysis in Patients. Presentation during two meetings: 27th Annual Research Showcase, Gainesville, FL; and EPI Research Day 2014, Gainesville, FL. Feb/2014 Feb/2014
118. Eric F. Egelund, A. Paige Brock, Ramiro Isaza, Robert P. Hunter, **Charles A. Peloquin**. The Pharmacokinetics of a Single Oral or Rectal Dose of Concurrently Administered Isoniazid, Rifampin, Pyrazinamide, and Ethambutol in Asian Elephants (*Elephas maximus*). Emerging Pathogens Institute, University of Florida. Gainesville, FL. February 2014.
119. Sara H Browne, Richard Haubrich, Heather McClendon\*, Lorenzo DiCarlo, **Charles Peloquin**, Kathleen Moser, Constance Benson Wirelessly Observed Therapy (WOT) Compared to Directly Observed Therapy (DOT) for the Treatment of TB. National TB Conference (NTCA) 2014, Atlanta, GA, June 11-13.
120. Aline Barth, Ravi Shankar P. Singh, Robert May, Judith Johnson, Ramiro Isaza, Henry Michael Blumberg, Sergo Vashakidze, **Charles Peloquin**, Hartmut Derendorf, Russell Kempker. Levofloxacin Dose Optimization for Multidrug-resistant Tuberculosis Based on Lung Microdialysis in Patients. American College of Clinical Pharmacology annual meeting September 14<sup>th</sup>–16<sup>th</sup> 2014, Atlanta, Georgia
121. A. Alsultan, Derby R, An G, **C.A. Peloquin**. Bayesian Estimation of Levofloxacin Pharmacokinetics in Patients with Tuberculosis. 2 meetings: 7<sup>th</sup> International Workshop on Clinical Pharmacology of TB drugs, Washington, DC, Sept 5, 2014 and Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC, Sept 5-9, 2014.
122. Horsburgh CR, Phillips PPJ, Mitnick CM, Diacon A, Gotuzzo E, Lecca L, Eisenach K, Dianis, N, Drusano G, **C. Peloquin**. Efficient Study Design to Determine optimal Drug Dosing for MDR-TB. 7<sup>th</sup> International Workshop on Clinical Pharmacology of TB drugs, Washington, DC, Sept 5, 2014.
123. A. Alsultan, Mendez M, **C.A. Peloquin**. Therapeutic Drug Monitoring of Second Line Tuberculosis Drugs. 7<sup>th</sup> International Workshop on Clinical Pharmacology of TB drugs, Washington, DC, Sept 5, 2014.
124. I. Zentner, L. Khensouvann, M. Kutzler, H. Schlecht, G.P. Bisson, **C. Peloquin**, C. Vinnard. A Urine Colorimetric Assay to Detect Low Peak Serum Concentrations of Pyrazinamide: A Proof-of-Concept Study. Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC, Sept 5-9, 2014.
125. W. W. Hope, T. J. Walsh, J. Goodwin, **C. Peloquin**, A. Howard, J. Kurtzberg, A. Menizabal, D. Confer, J. Bulitta, M. Neely, L. Baden, J. Wingard. Relationship Between Voriconazole Concentrations and the Probability of Breakthrough Fungal Infections. Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC, Sept 5-9, 2014.

## XI. E. Abstracts

126. N. Bannietis , R. Sharma, I. Hand, **C. Peloquin**, K. Stephan, H. R. Margaret. Steady State Pharmacokinetics of Linezolid (LZ) Suspension in Premature Infant with Osteomyelitis. Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC, Sept 5-9, 2014.
127. Lorna Khensouvann, Michele Kutzler, Tawanda Gumbo, Jotam Pasipanodya, Hans Schlecht, Gregory P. Bisson, **Charles Peloquin**, Christopher Vinnard. Urine Colorimetry to Detect Low Rifampicin Bioavailability: A Proof-of-Concept Study. Submitted to 45th Union World Conference on Lung Health, 2014.
128. Sara Browne\*, Richard Haubrich, Constance Benson, Kathleen Moser, Lorenzo DiCarlo, **Charles Peloquin**. Wirelessly Observed Therapy (WOT): A New Paradigm in TB Therapy Monitoring. Conference on Retrovirus and Opportunistic Infections (CROI) 2015, Seattle, Washington, February 23-26, 2015
129. Tobias Heinrichs, Robert May, Russell Kempker, Judith Johnson, **Charles Peloquin**, Hartmut Derendorf. Moxifloxacin and Pyrazinamide Dose Optimization for Multidrug-resistant and Extensively Drug-resistant Tuberculosis Annual Meeting of the American College of Clinical Pharmacology, September 27–29, 2015, San Francisco, CA
130. Alyshia Wiggins, Abdullah Alsultan, **Charles Peloquin**. Therapeutic Drug Monitoring of Ethambutol in Patients with Tuberculosis. 8<sup>th</sup> Workshop, San Diego, CA, September 17, 2015
131. E Haraus, J Leigh, TJ Zagurski, J Furin, **CA Peloquin**. Stability of Second-Line Tuberculosis Drugs Mixed with Readily Available, Nutritious Foods. 8<sup>th</sup> Workshop, San Diego, CA, September 17, 2015
132. A. Sultan, B. Mahjoub, **C.A. Peloquin**. Determining protein binding of levofloxacin and moxifloxacin in vitro using ultrafiltration. 8<sup>th</sup> Workshop, San Diego, CA, September 17, 2015
133. S. Browne, R. Haubrich, K. Moser, **C. Peloquin**, L. di Carlo, C. Benson. Digitizing MTB Medicines: Using compounding methods to enable mobile capture of MTB medication adherence. 8<sup>th</sup> Workshop, San Diego, CA, September 17, 2015

## **XI. F. Presentations at Scientific Meetings (from 2009)**

### **F. 1. Invited International Lectures**

31. Symposium: Important new dosage regimens for TB: New PK understanding. Infectious Disease Society of America. Philadelphia, PA November 1, 2009
32. Symposium: TB / HIV Update: Drug-Drug Interactions. International Union Against TB and Lung Disease, North American Region. March 11, 2010, Orlando, FL
33. Drug Interactions. Forum to Promote TRIUMPH: TB Research in Underserved Maternal and Pediatric Populations with HIV. July 29-30, 2010 Bethesda, MD
34. Studying PK/PD of TB drugs - A daunting challenge. International Society of Anti-Infective Pharmacology Post-ICAAC Symposium, Wednesday, September 15th, 2010, Boston, MA
35. Anti-Mycobacterial Drugs. Infectious Disease Society of America (IDSA) 48<sup>th</sup> Annual Meeting, October 21-24, 2010, Vancouver, BC, Canada
36. Pharmacokinetics of Antituberculosis Agents: Current Issues. 50<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17-20, 2011, Chicago, IL.
37. Pharmacodynamics, Drug interactions, Intolerance and Toxicity of TB drugs. Haiti's National strategies for universal treatment and prevention of tuberculosis: development of policies and guidelines for MDR TB diagnosis and treatment. Ministere de la Sante Publique et de la Population, Petion-Ville, Haiti July 2 – 3, 2012
38. Population pharmacokinetics of TB drugs are predictable. Scientific meeting MDR-TB. Pharmacokinetics: individually or population-wise? Wenkebach Instituut, University Center of Rehabilitation, Beatrixoord, ND Haren, The Netherlands, March 8, 2013.
39. Accounting for Variability: Pharmacokinetics in TB Treatment. Gordon research Conference: Tuberculosis Drug Development. Renaissance Tuscany Il Ciocco Resort in Lucca (Barga) Italy, July 25, 2013.
40. Pharmacokinetic Variability and Tuberculosis Treatment Outcomes. Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC, Sept 5-9, 2014.
41. Update on Multidrug Resistant Tuberculosis. ACCP Annual Meeting, 2014, Austin, TX, October 12-15.
42. Individualized Antibiotic Therapy. Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Diego, CA, Sept 17-21, 2015.

**XI. F. Presentations at Scientific Meetings (from 2009)**  
**F. 2. Invited National Lectures**

10. Pharmacokinetics 101.  
CDC Tuberculosis Clinical Trial Consortium (TBTC) Study Coordinators Meeting, Atlanta GA, October 17, 2007 South Eastern TB Controllers Meeting, Biloxi, MS, October 20, 2009
11. MDR-TB: An Update on Treatment Options and Management.  
ACCP Annual Meeting, Louisville, KY, October 21, 2008.
12. Pharmacokinetics & Pharmacodynamics: Why Do TB Drugs Fail?  
Southeastern National TB Center (SNTC) National Webinar: Grand Rounds –  
Wednesday, October 7, 2009, 11:00 a.m. - 12:30 p.m. EDT
13. TB and HIV, Clinical Challenges and New Solutions.  
UF COP National Advisory Board meeting, November 6, 2009, Gainesville, FL
14. Pharmacokinetics and Pharmacodynamics in the treatment of TB. National TB Conference,  
National Society of TB Clinicians Annual Meeting, Atlanta, GA, June 21, 2010.
15. Drug-drug interactions: What to keep on your radar. Common culprits and newer agents. National TB  
Conference, National Society of TB Clinicians Annual Meeting, Atlanta, GA, June 13, 2011.
16. The Role of Therapeutic Drug Monitoring. 6th Annual TB Medical Consultant's Meeting, New Jersey  
National TB Center, Newark, NJ, November 7-8, 2012.
17. Pharmacology and Pharmacokinetics of TB Drugs. Southeastern National TB Center (SNTC)  
Comprehensive Clinical TB Course, Gainesville, FL, December 4, 2012.
18. Pharmacology and Pharmacokinetics of TB Drugs. Southeastern National TB Center (SNTC)  
Comprehensive Clinical TB Course, Gainesville, FL, October 9, 2013.
19. Pharmacology and Pharmacokinetics of TB Drugs. Southeastern National TB Center (SNTC)  
Comprehensive Clinical TB Course, Gainesville, FL, December 11, 2013.
20. Therapeutic Drug Monitoring: Nuts and Bolts. Southeastern National TB Center (SNTC) Webinar,  
Gainesville, FL, January 29, 2014.
21. Pharmacology and Pharmacokinetics of TB Drugs. Southeastern National TB Center (SNTC)  
Comprehensive Clinical TB Course, Gainesville, FL, March 5, 2014.
22. Therapeutic Drug Monitoring: Nuts and Bolts. 2014 World TB Day Symposium: New Challenges and  
New Tools in the Diagnosis and Management of Tuberculosis, Vanderbilt University, Nashville, TN, April  
1, 2014.
23. Pharmacology and Pharmacokinetics of TB Drugs. Southeastern National TB Center (SNTC)  
Comprehensive Clinical TB Course, Gainesville, FL, October 8, 2014.

24. Pharmacology and Pharmacokinetics of TB Drugs. Southeastern National TB Center (SNTC) Comprehensive Clinical TB Course, Gainesville, FL, December 10, 2014.
25. Pharmacology and Pharmacokinetics of TB Drugs, Mayo Conference (Webinar) February 11, 2015.
26. Pharmacology and Pharmacokinetics of TB Drugs. Southeastern National TB Center (SNTC) Comprehensive Clinical TB Course, Gainesville, FL, May 6, 2015.
27. Optimizing the Use of Long Half Life Drugs. NIH workshop: Developing Novel Strategies to Optimize Design of TB Drug Combinations. June 16-17, 2015, Rockville, MD.
28. Advanced Concepts in Pediatric TB - Webinar Series - Pharmacotherapeutics of TB Drugs. Southeastern National TB Center (SNTC), Gainesville, FL, June 18, 2015
29. Maximizing Rifamycins. Southeastern National TB Center (SNTC) Webinar, Gainesville, FL, January 27, 2016



### F. 3. Other Lectures (from 2009)

Pharmacokinetics and Pharmacodynamics in the treatment of TB.

ID Conference, UF, Gainesville, FL, January 8, 2010

ID Conference, Florida Department of Health, Jacksonville, FL, March 10, 2010

TB and Respiratory Disease Institute, American Lung Association of North Carolina, July 12, 2010

Research Conference, UF Center for AIDS/HIV Research, Jacksonville, FL, July 19, 2010

Orlando Regional Medical Center, Orlando, FL, July 23, 2010

Tuberculosis. Pediatric Pulmonary Conference. June 11, 2010, Gainesville, FL

Pharmacokinetics 101. Grand Rounds, UF Center for AIDS/HIV Research, Jacksonville, FL, July 19, 2010

Emerging Pathogens. FSHP 44th Annual Meeting. Orlando, FL. July 30-August 1, 2010.

Drug-Drug Interactions and Issues Related to TB Drugs in HIV Patients, Area Health Education Centers (AHEC) Sumposium: An HIV/AIDS Update. September 1, 2010, Gainesville, FL

Pharmacokinetics of Anti-tuberculosis Agents and Therapeutic Drug Monitoring. At the Tuberculosis Clinical Update, November 16, 2011, Richmond, VA

Drug-Drug Interactions and Issues Related to TB Drugs in HIV Patients, Area Health Education Centers (AHEC) Sumposium: An HIV/AIDS Update. August 7, 2013, Gainesville, FL

Therapeutic Drug Monitoring and Tuberculosis, Practical Considerations. University of Houston, July 3, 2014.

Pharmacokinetic Variability and Tuberculosis Treatment Outcomes. University of Florida Pediatric Noon Conference. January 27, 2015.

Pharmacokinetics of TB drugs in HIV Co-infected Patients. St Jude Children's Research Hospital and University of South Florida. April 7, 2015.

Pole Vaulting with Rifamycins. PTR Seminar December 10, 2015.

## E. Books and Guides

1. Contributor to: CDC. Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis [online]. 2007. Available from URL: [http://www.cdc.gov/tb/TB\\_HIV\\_Drugs/default.htm](http://www.cdc.gov/tb/TB_HIV_Drugs/default.htm)
2. Contributor to: Francis J. Curry National Tuberculosis Center and State of California Department of Public Health, 2008: Drug-Resistant Tuberculosis: A Survival Guide for Clinicians, 2nd edition. Braun JT, Daley CL, Desmond EP, Flood JM, Kawamura LM, Loeffler AM, Mase SR, Pai M, **Peloquin C**, Raftery A, Salfinger M, Schechter G, Seaworth BJ, Smith KL, Wallis K. Editors: Loeffler AL, Daley CL, Flood JM, Schechter G.
3. Contributor to: Francis J. Curry National Tuberculosis Center and State of California Department of Public Health, 2009: Tuberculosis Drug Information Guide. Loeffler AL, **Peloquin CA**, Schechter G. Editors: Loeffler AL, Schechter G, Daley CL, Flood JM.
4. Contributor to: Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents. Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Vol. 58 / RR-4, April 10, 2009.
5. Contributor to: Loeffler AL, **Peloquin CA**, Schechter G. Editors: Loeffler AL, Schechter G, Daley CL, Flood JM. Francis J. Curry National Tuberculosis Center and State of California Department of Public Health, 2012: Tuberculosis Drug Information Guide, 2nd edition.
6. Contributor to: Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents. Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Downloaded from <http://aidsinfo.nih.gov/guidelines> on 5/14/2013
7. Contributor to: CDC. Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis. 2013. Available at [URL:http://www.cdc.gov/tb/publications/guidelines/TB\\_HIV\\_Drugs/pdf/tbhiv.pdf](http://www.cdc.gov/tb/publications/guidelines/TB_HIV_Drugs/pdf/tbhiv.pdf)
8. Contributor to: Francis J. Curry National Tuberculosis Center and State of California Department of Public Health, 2016: Drug-Resistant Tuberculosis: A Survival Guide for Clinicians, 3rd edition. Barry PM, Cattamanchi A, Chen L, Daley CL, Flood JM, Griffith DE, Lin SYG, Loeffler AM, Pascopella L, **Peloquin CA**, Raftery A, Schechter GF, Seaworth BJ, True L. Editors: Chen L, Schechter GF, Daley CL, Flood JM, Loeffler AM, Wallis K.
9. Contributor to: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis  
Payam Nahid, Susan E. Dorman, Narges Alipanah, Pennan M. Barry, Jan L. Brozek, Adithya Cattamanchi, Lelia H. Chaisson, Richard E. Chaisson, Charles L. Daley, Malgosia Grzemska, Julie M. Higashi, Christine S. Ho, Philip C. Hopewell, Salmaan A. Keshavjee, Christian Lienhardt, Richard Menzies, Cynthia Merrifield, Masahiro Narita, Rick O'Brien, **Charles A. Peloquin**, Ann Raftery, Jussi Saukkonen, H. Simon Schaaf, Giovanni Sotgiu, Jeffrey R. Starke, Giovanni Battista Migliori, and Andrew Vernon.  
Clin Infect Dis. 2016 Aug 10. pii: ciw376. [Epub ahead of print] PMID: 27516382

## F. Manuscripts Accepted for Publication

Eric F. Egelund, Ramiro Isaza, Abdullah Alsultan, **Charles A. Peloquin**. Isoniazid and Rifampin Pharmacokinetics in Two Asian Elephants Two Asian Elephants with Tuberculosis. *Journal of Zoo and Wildlife Medicine*

## G. Chapters Accepted for Publication

Namdar R, Lauzardo M, **Peloquin CA**. Tuberculosis. In DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, Eds. *Pharmacotherapy: A pathophysiologic approach*, 10th ed.

## H. Manuscripts Submitted for Publication

Savic RM, Weiner M, Mac Kenzie W, Engle M, Whitworth WC, Johnson JL, Nsubuga P, Nahid P, Nhung NV, **Peloquin CA**, Dooley KE, and Dorman SE for the Tuberculosis Trials Consortium of the Centers for Disease Control and Prevention. Rifapentine Pharmacokinetics and Pharmacodynamics in Two Clinical Trials During Intensive Phase Treatment of Adults with Pulmonary Tuberculosis

Hamadeh IS, Klinker KP, Borgert SJ, Richards AM, Li W, Mangal N, Hiemenz JW, Schmidt S, Langae TY, **Peloquin CA**, Johnson JA, Cavallari LH Impact of the CYP2C19 Ultrarapid Metabolizer Phenotype on Voriconazole Exposure in Adults with Invasive Fungal Infections.

Simpson G, Zimmerman R, Shashkina E, Chen L, Richard M, Bradford C, Drago G, Saiers R, Daley C, Planet P, Narechania A, **Peloquin C**, Mathema B, Kreiswirth B. Epidemiology, genomics and clinical challenges associated with M. tuberculosis treatment and transmission among Asian elephants in captivity

Sara H Browne, Charles Peloquin, Frank Santillo, Richard Haubrich, Kathleen Moser, George Savage, Constance Benson, Terrence Blaschke. Digitizing Medicines: Evaluation of compounding method combining oral medications with ingestion sensors.

## H. Manuscripts Submitted for Publication

Sampson Antwi, Hongmei Yang, Anthony Enimil, Anima M. Sarfo, Fizza S. Gillani, Daniel Ansong, Albert Dompoh, Antoinette Orstin, Theresa Opoku, Dennis B, Lubbe Wiesner, Jennifer Norman, **Charles A. Peloquin**, A Kwara. Effect of HIV infection on the Pharmacokinetics of the First-line Antituberculosis Drugs in Children with Tuberculosis

Abdullah Alsultan, **Charles A. Peloquin**. Reply to “Isoniazid minimal inhibitory concentrations of tuberculosis strains with katG mutation” *IJTLD*

**Peloquin CA** et al. Author Reply to Alffenaar et al, Letter to CID regarding 2016 ATS/CDC/IDSA Drug Susceptible Tuberculosis Treatment Guidelines

Revised 9-16